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892The ROCKETAF (Rivaroxaban
Once-daily oral Direct Factor
Xa Inhibition Compared with
Vitamin K Antagonism for Pre-
vention of Stroke and Embolism
Trial in Atrial Fibrillation) de-
monstrated that rivaroxaban was
noninferior to warfarin for the
prevention of stroke and systemic
embolism (1). Although major
and nonmajor clinically relevant
bleeding rates were also similar,
rivaroxaban led to a lower risk of
intracranial hemorrhage and fatal
bleeding. In contrast, rivaroxaban
caused higher rates of bleeding
from gastrointestinal (GI) sites
and bleeding that led to a drop
in hemoglobin level or required
transfusion. The effect of rivar-oxaban in stroke/systemic embolism prevention and safety
was consistent across a broad range of patient baseline char-
acteristics (1), suggesting that once-daily, ﬁxed-dose rivar-
oxaban is an alternative to adjusted-dose warfarin in patients
with nonvalvular atrial ﬁbrillation (AF) who are at moderate-
to-high risk for stroke. We report on additional safety results
of rivaroxaban compared with warfarin from the ROCKET
AF trial. Furthermore, because several bleeding risk scores
have been developed from data on patients receiving warfarin
(2–7) and their applicability (8,9)dparticularly to newer
anticoagulants (10)dis uncertain, we investigated factors
associated with major bleeding in AF patients in the
ROCKET AF trial.Methods
The ROCKET AF trial design. The ROCKET AF
design has been published (1,11). The primary study
objective was to establish the noninferiority of rivaroxabanpport from Johnson & Johnson, GE Healthcare,
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Johnson, Pﬁzer, Sanoﬁ-Aventis, Biotronik, Inc.,compared with warfarin for the prevention of stroke or
systemic embolism in patients with nonvalvular AF. The
trial randomized 14,264 patients with AF who were at
moderate-to-high risk for stroke. Elevated risk was indicated
by a history of stroke, transient ischemic attack (TIA), or
systemic embolism or at least 2 of the following risk factors:
heart failure or a left ventricular ejection fraction 35%;
hypertension; age 75 years; or diabetes mellitus. The
proportion of patients who had not had a previous ischemic
stroke, TIA, or systemic embolism and who had no more
than 2 risk factors was limited to 10% of the cohort for each
region; the remainder of patients were required to have had
either previous thromboembolism or 3 or more risk factors.
Key exclusion criteria included: active internal bleeding; a
history of or condition associated with increased bleeding
risk (e.g., major surgical procedure or trauma 30 days;
clinically signiﬁcant GI bleeding 6 months; history of
intracranial, intraocular, spinal, or atraumatic intra-articular
bleeding; chronic hemorrhagic disorder; known intracranial
neoplasm, arteriovenous malformation, or aneurysm; platelet
count <90,000/ml at the screening visit; sustained uncon-
trolled hypertension [i.e., systolic blood pressure (SBP)
180 mm Hg and/or diastolic blood pressure (DBP)
100 mm Hg]; acetylsalicylic acid (ASA) >100 mg daily or
in combination with thienopyridines at the time of
screening; anticipated need for 14 days of treatment with a
nonsteroidal anti-inﬂammatory drug; anemia [hemoglobin
<10 g/dl] at the screening visit; calculated creatine
clearance <30 ml/min at the screening visit; or signiﬁcant
liver disease [e.g., acute clinical hepatitis, chronic active
hepatitis, cirrhosis] or alanine transferase >3 the upper
limit of normal).
Patients were randomized to receive ﬁxed-dose rivarox-
aban 20 mg daily (or 15 mg daily in patients with a creati-
nine clearance of 30 to 49 ml/min) or adjusted-dose warfarin
(target international normalized ratio [INR]: 2.5; range 2.0
to 3.0). Patients in each group also received a placebo tablet
to maintain blinding. A point-of-care device was used to
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893interactive voice response system to generate either real INR
values (for patients in the warfarin group to adjust the dose)
or sham values (for patients in the rivaroxaban group
receiving placebo warfarin).
All appropriate national regulatory authorities and ethics
committees approved the study. All patients provided
written informed consent.
Outcome deﬁnitions. All primary and secondary outcome
events were adjudicated by an independent clinical endpoint
committee blinded to treatment assignment.
The principal safety endpoint was deﬁned as major
bleeding or nonmajor clinically relevant bleeding. Major
bleeding was deﬁned as that which was clinically overt and
associated with any of the following: fatal outcome; involve-
ment of a critical anatomic site (intracranial, spinal, ocular,
pericardial, articular, retroperitoneal, or intramuscular with
compartment syndrome); fall in hemoglobin concentration
>2 g/dl; transfusion of >2 U of whole blood; or packed red
blood cells (12). Nonmajor clinically relevant bleeding was
deﬁned as overt bleeding not meeting criteria for major
bleeding but requiring medical intervention, unscheduled
contact (visit or telephone) with a physician, temporary
interruption of the study drug (i.e., delayed dosing), pain, or
impairment of daily activities.
Statistical analysis. We examined the effect of rivaroxaban
and warfarin on the risk of major bleeding. Bleeding end-
points are presented as rates/100 patient-years of follow-up.
All analyses of rates of bleeding are based on the ﬁrst event
in the safety population during treatment. We considered
the issue of competing risk (due to death) and examined the
cumulative incidence estimates of major bleeding; however,
because the differences between the methods were minimal
(data not shown), we used the Kaplan-Meier method. The
Cox model was used to derive hazard ratios (HRs) and
conﬁdence intervals (CIs) for the rivaroxaban versus warfarin
comparison. Baseline characteristics of patients with and
without a major bleeding event were summarized as fre-
quencies and percentages for categorical variables and me-
dian and quartiles for continuous variables.
The Cox model was also used to compare patients with
and without major bleeding in terms of demographic and
clinical characteristics; for each characteristic, a univariate
Cox model for the risk of major bleeding was derived. The
following candidate variables included those pre-speciﬁed in
the statistical analysis plan of the trial plus those in the
HAS-BLED (Hypertension, Abnormal renal/liver function,
Stroke, Bleeding history, Labile International Normal-
ized Ratio, Elderly, Drugs/alcohol) (7) and ATRIA
(AnTicoagulation and Risk factors In Atrial ﬁbrillation) (6)
bleeding scores: age; sex; body mass index; SBP and DBP;
type of AF (persistent, paroxysmal, or newly diagnosed/new
onset); history of stroke; TIA or systemic embolism; history
of heart failure; diabetes mellitus; myocardial infarction;
peripheral arterial disease; chronic obstructive pulmonary
disease (COPD); alcohol use; liver disease; prior GI
bleeding; labile INR; ASA use (before randomization);prior vitamin K antagonist use; creatinine clearance; and
anemia (hemoglobin <13 g/dl in men and <12 g/dl in
women). Variables considered in other bleeding scores
(2,3,5), such as history of malignancy, prior peptic ulcer
disease, prior (non-GI) bleeding, genetic factors, excessive
fall risk or neuropsychiatric disease, and prior ethanol or
drug abuse, were not recorded in the ROCKET AF trial.
Continuous variables were tested for linearity with
restricted cubic splines. Systolic and DBPs were transformed
with linear spline. Variables were selected for inclusion in
the regression model with a backward selection method with
signiﬁcance level to stay in the model set to 0.05.
All analyses were performed with the use of SAS software
(version 9.2, SAS Institute, Inc., Cary, North Carolina). A
2-sided p value <0.05 was considered statistically signiﬁ-
cant. The authors of the paper had full access to the data and
planned the statistical analyses.Results
Patient characteristics and treatments. As published (1),
the median age was 73 years (25th, 75th percentiles: 65, 78),
40% were women, 91% had hypertension, 63% had a history
of heart failure, 40% had diabetes, 17% had a prior
myocardial infarction, 11% had a history of COPD, and
55% had a history of stroke, systemic embolism, or TIA.
The median CHADS2 (Congestive heart failure, hyperten-
sion, age >75 years, Diabetes, prior Stroke/TIA/non-central
nervous system thromboembolism [doubled]) score was 3
(3,4). Atrial ﬁbrillation was persistent in 81%, 62% had
previously used a vitamin K antagonist, and 37% had used
ASA before randomization. During the course of the study,
35% of patients in the rivaroxaban group and 36% of those
in the warfarin group took ASA concurrently with the
assigned study drug. Among patients in the warfarin group,
INR values were within the therapeutic range (2 to 3) a mean
of 55% of the time (median: 58%; 25th, 75th percentiles
range: 43%, 71%) (13). Warfarin-experienced patients had a
mean time in the therapeutic range (TTR) of 61%, whereas
warfarin-naive patients had a mean TTR of 47%. The mean
time with an INR <2 was 29% and >3 was 16% (13).
Bleeding. Table 1 presents the risk of the principal safety
endpoint, individual endpoint components including
transfusions, and minimal bleeding according to random-
ized treatment allocation. Figure 1 presents Kaplan-Meier
curves for major bleeding. Compared with warfarin, rivar-
oxaban had a similar risk of the principal safety endpoint,
including major and nonmajor clinically relevant bleeding.
Although rivaroxaban caused a signiﬁcantly higher risk of
hemoglobin decrease 2 g/dl and transfusion compared
with warfarin, critical bleeding and fatal bleeding were
signiﬁcantly lower in rivaroxaban-treated patients. Intra-
cranial hemorrhage was signiﬁcantly lower in the rivarox-
aban group (0.5 vs. 0.7, HR: 0.67; 95% CI: 0.47 to 0.93).
Minimal bleeding (not included in the primary safety end-
point) was similar in the rivaroxaban and warfarin groups
Table 1 Event Rates and HRs and 95% CIs for Bleeding Events
Events (Rate)
HR (95% CI) p Value
Rivaroxaban
(n ¼ 7,111)
Warfarin
(n ¼ 7,125)
Principal safety endpoint 1,475 (14.91) 1,449 (14.52) 1.03 (0.96–1.11) 0.442
Major 395 (3.60) 386 (3.45) 1.04 (0.90–1.20) 0.576
Hemoglobin/hematocrit drop 305 (2.77) 254 (2.26) 1.22 (1.03–1.44) 0.019
Transfusion 183 (1.65) 149 (1.32) 1.25 (1.01–1.55) 0.044
Critical organ bleeding 91 (0.82) 133 (1.18) 0.69 (0.53–0.91) 0.007
Death 27 (0.24) 55 (0.48) 0.50 (0.31–0.79) 0.003
Nonmajor clinically relevant 1,185 (11.80) 1,151 (11.37) 1.04 (0.96–1.13) 0.345
Minimal 258 (2.35) 226 (2.03) 1.16 (0.97–1.39) 0.102
Event rates/100 patient-years.
CI ¼ conﬁdence interval; HR ¼ hazard ratio.
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894(2.4 vs. 2.0, HR: 1.16; 95% CI: 0.97 to 1.39). Epistaxis
(6.9% vs. 5.7%; p  0.001) and hematuria (2.7% vs. 2.2%;
p ¼ 0.011) were reported more frequently as an adverse
event in the rivaroxaban group.
Table 2 presents the risks of major and nonmajor clinically
relevant bleeding by site. Among the 1,063 patients with
a major or nonmajor clinically relevant bleeding event,
warfarin (active or placebo) dose was reduced in 116 (4%)
patients. The study drug was temporarily discontinued but
then restarted in 1,337 (46.2%) and permanently dis-
continued in 381 (13.1%). Bleeding led to permanent study
drug discontinuation in 322 (4.5%) rivaroxaban and 286
(4%) warfarin patients (absolute difference 0.5; 95% CI:
0.2 to 1.2).
Major bleeding. Figure 2 presents the HRs for major
bleeding in patients randomized to receive rivaroxaban
compared with warfarin in key subgroups according to pa-
tient baseline characteristics. The risk of major bleeding
increased with increasing age, although there were noFigure 1 Major Bleeding by Treatment
Kaplan-Meier curves for major bleeding for the treatment groups. HR ¼ hazard ratio.apparent differences between rivaroxaban and warfarin in
each age category (<65, 65 to 74, 75 years; p for
interaction ¼ 0.59). The relative risk of major bleeding with
rivaroxaban versus warfarin was comparable in those <75
years of age (n ¼ 8,007: 2.7% vs. 2.8%; HR: 0.96; 95%
CI: 0.78 to 1.19) and those 75 years or older (n ¼ 6,164:
4.9% vs. 4.4%; HR: 1.11; 95% CI: 0.92 to 1.34) (p for
interaction ¼ 0.34). The relative risk of intracranial hem-
orrhage for rivaroxaban versus warfarin was statistically
signiﬁcantly lower in those under 75 years (0.37% vs. 0.68%;
HR: 0.54; 95% CI: 0.33 to 0.89) and numerically lower in
those 75 years or older (0.66% vs. 0.83%; HR: 0.80; 95% CI:
0.50 to 1.28) (p value for interaction ¼ 0.27). There was a
statistically signiﬁcant p value for interaction when
comparing the HRs for major bleeding across regions, with
the North American cohort having the highest overall
rates, including a signiﬁcantly higher frequency in the
rivaroxaban-treated patients (7.1% vs. 5.0%; HR: 1.43; 95%
CI: 1.12 to 1.82).
Table 2
Major Bleeding or Nonmajor Clinically Relevant
Bleeding by Site
Rivaroxaban
(n ¼ 7,111)
Warfarin
(n ¼ 7,125)
Major bleeding or nonmajor clinically
relevant bleeding
1,475 (20.7) 1,449 (20.3)
GI (upper, lower, and rectal)* 394 (5.5) 290 (4.1)
Intracranialy 55 (0.77) 84 (1.18)
Intraparenchymaly 37 (0.52) 56 (0.79)
Nontraumaticy 33 (0.46) 54 (0.76)
Traumatic 4 (0.06) 2 (0.03)
Intraventricularz 13 (0.18) 30 (0.42)
Subdural hematomay 14 (0.20) 27 (0.38)
Subarachnoid 7 (0.10) 14 (0.20)
Epidural hematoma 0 1 (0.01)
Macroscopic hematuriaz 243 (3.4) 187 (2.6)
Bleeding associated with
noncardiac surgery
53 (0.75) 47 (0.66)
Intraocular/retinal 17 (0.24) 24 (0.34)
Intra-articular 16 (0.23) 21 (0.29)
Epistaxis 303 (4.3) 275 (3.9)
Values are n (%). Patients can be counted in multiple lines, including for intracranial bleeding.
*p < 0.0001. yp < 0.05. zp < 0.01; no adjustments for multiple comparisons were made.
GI ¼ gastrointestinal.
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895Table 3 presents the baseline characteristics of all patients
in the ROCKET AF trial according to whether or not they
experienced a major bleeding event. Patients with a major
bleed (n ¼ 781) were more likely to be older (median 75 vs.
73 years, p < 0.0001), current or prior smokers (40.2% vs.
33.2%, p < 0.0001), have a history of prior GI bleeding
(7.8% vs. 3.3%, p < 0.0001), have mild anemia at baseline
(25.1% vs. 13.5%, p < 0.0001), use ASA before randomi-
zation (42.3% vs. 36.2%, p < 0.0001), and have a lower
baseline calculated creatinine clearance (63 vs. 68 ml/min,
p < 0.0001); they were less likely to be female (34.3% vs.
40.0%, p ¼ 0.0017) or to have a prior stroke or TIA (46.2%
vs. 52.7%, p ¼ 0.0004), compared with those without a
major bleed (n ¼ 13,455).
Tables 4 and 5 present the number of major bleeding
events, patient-years of follow-up, and the number of
bleeding events/100 patient-years according to the
contemporary bleeding risk stratiﬁcation schemas HAS-
BLED (7) and ATRIA (6). The predictive value of these
schemas deteriorated when applied to the ROCKET AF
population when compared with the original derivation
cohorts (for HAS-BLED: c-statistic 0.55 [0.53 to 0.57] vs.
0.72 [0.65 to 0.79] [7] and for ATRIA: 0.60 [0.58 to 0.63]
vs. 0.74 [0.70 to 0.78]) (6).
Table 6 presents the multivariable model examining fac-
tors associated with major bleeding derived from the
ROCKET AF cohort. Increasing age, baseline DBP 90
mmHg, history of COPD, GI bleeding, prior ASA use, and
anemia were associated with an increased risk, whereas
female sex and DBP <90 mm Hg were associated with a
decreased risk for major bleeding. Figure 3 illustrates the
“v-shaped” univariate relationship of both baseline SBP and
DBP with the risk of major bleeding. Study treatment wasnot independently associated with major bleeding (p ¼ 0.38)
when added to the model; however, when we investigated
a separate model restricted to patients randomized to
rivaroxaban, female sex and DBP <90 mm Hg were not
independently associated with major bleeding, whereas body
mass index and peripheral artery disease were of borderline
signiﬁcance (data not shown). None of the independent
predictors for bleeding interacted with study treatment, with
the exception of prior history of GI bleeding (p ¼ 0.002).
Patients on a regimen of rivaroxaban compared with
warfarin were at higher risk of major bleeding if they had a
prior history of GI bleeding (HR: 2.33; 95% CI: 1.39 to
3.88), whereas there was a similar risk for major bleeding if
there was no prior history of GI bleeding (HR: 1.00; 95%
CI: 0.86 to 1.16). However, prior history of GI bleeding was
included in the major bleeding model, and adding the
treatment by prior GI bleeding interaction term to the
prediction model minimally improved the c-index from
0.6445 to 0.6455.
Discussion
In this large population of patients with nonvalvular AF at
moderate-to-high risk for stroke, there were no signiﬁcant
differences in the rates of major bleeding between rivarox-
aban and warfarin. A multivariable model derived from the
ROCKET AF cohort demonstrated that several baseline
clinical characteristicsdage, female sex, DBP, history of
COPD, GI bleeding, prior ASA use, and anemiadwere
associated with major bleeding risk. This model was more
predictive of major bleeding in the ROCKET AF cohort
than the HAS-BLED or ATRIA bleeding risk scores.
Apart from prior GI bleeding, which was signiﬁcantly
associated with major bleeding in patients randomized to
rivaroxaban but not warfarin, the other risk factors had the
same association with bleeding in both randomized oral
anticoagulation groups.
Other studies comparing new oral anticoagulants with
warfarin. Although ROCKET AF patients were at in-
creased risk for both stroke (e.g., 55% with prior stroke, TIA,
or systemic embolism and a median CHADS2 risk score of
3) and bleeding (e.g., median age 73 years, 91% with hy-
pertension), the major bleeding rates were similar to those in
recent studies (14–18). However, cross-trial comparisons are
challenging, because the patient populations and associated
risk factors for stroke and bleeding, deﬁnitions of bleeding,
and newer anticoagulants were clearly different in these trials.
Of note, Eikelboom et al. (17) reported an important age 
treatment interaction with the 2 different dabigatran doses
compared with warfarin, suggesting that the risk of extra- but
not intracranial bleeding was increased with the 150-mg
twice-daily dose in those 75 years of age. In the
ROCKET AF trial, we did not observe an age  treatment
interaction with rivaroxaban compared with warfarin; the
relative risk for major bleeding was similar, regardless of age,
whereas intracranial bleeding risk was lower with rivaroxaban
Figure 2 Major Bleeding in Key Subgroups
On-treatment (safety population) major bleeding in key subgroups according to patient baseline characteristics. AF ¼ atrial ﬁbrillation; ASA ¼ acetylsalicylic acid; BMI ¼ body
mass index; CHADS ¼ congestive heart failure, hypertension, age 75 years, diabetes mellitus, prior stroke, transient ischemic attack (TIA), or non–central nervous system
thromboembolism (doubled); CI¼ conﬁdence interval; CNS¼ central nervous system; CrCl¼ creatinine clearance; TIA¼ transient ischemic attack; VKA¼ vitamin K antagonists.
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896(statistically in those <75 years and numerically in those
75 years with a nonsigniﬁcant p value for interaction).
Bleeding location. Although mucosal bleeding (e.g.,
epistaxis, hematuria, GI) was increased, intracranial hem-
orrhage with rivaroxaban was decreased. The consistentlylower rates of intracranial bleeding observed with the newer
oral anticoagulants versus warfarin might be due to the effect
on a single target in the hemostatic system (e.g., factor Xa
inhibition) compared with the multiple targets by warfarin
(17). In addition, it has been speculated that the presence of
Table 3 Baseline Characteristics of ROCKET AF Patients According to Major Bleeding Events
Characteristic
Major Bleed
(n ¼ 781)
No Major Bleed
(n ¼ 13,455) p Value
Age, yrs 75 (69–80) 73 (65–78) <0.0001
<65 yrs 118 (15.1) 3,170 (23.6)
<0.000165–74 yrs 236 (30.2) 4,497 (33.4)
75 yrs 427 (54.7) 5,788 (43.0)
Female 268 (34.3) 5,377 (40.0) 0.0017
Race 0.21
White 633 (81.1) 11,225 (83.4)
Black 9 (1.1) 170 (1.3)
Asian 114 (14.6) 1,667 (12.4)
Other 25 (3.2) 393 (2.9)
Body mass index, kg/m2 28.0 (25.1–32.0) 28.2 (25.1–32.0) 0.42
SBP, mm Hg 130 (120–140) 130 (120–140) 0.12
DBP, mm Hg 80 (70–85) 80 (70–84) <0.0001
AF type
Persistent/permanent 638 (81.7) 10,887 (80.9)
0.42Paroxysmal 131 (16.8) 2,380 (17.7)
Newly diagnosed 12 (1.5) 188 (1.4)
Medical history
Hypertension 705 (90.3) 12,182 (90.5) 0.78
Diabetes mellitus 334 (42.8) 5,349 (39.8) 0.05
Coronary artery disease 318 (40.7) 5,142 (38.2) 0.13
Heart failure 466 (59.7) 8,428 (62.7) 0.35
LV dysfunction (<35% EF)* 528 (84.9) 8,431 (83.8) 0.82
Stroke/TIA 361 (46.2) 7,090 (52.7) 0.0004
Non-CNS systemic embolism 20 (2.6) 537 (4.0) 0.052
CHADS2 score 3 (3–4) 3 (3–4) 0.52
CHADS2 score >3 329 (42.1) 5,846 (43.5) 0.79
Myocardial infarction 152 (19.5) 2,308 (17.2) 0.033
Peripheral arterial disease 59 (7.6) 777 (5.8) 0.02
COPD* 111 (14.2) 1,382 (10.3) <0.0001
Liver disease 38 (4.9) 708 (5.3) 0.62
Alcohol use* 277 (35.5) 4,767 (35.4) 0.43
Current/prior smoking* 314 (40.2) 4,467 (33.2) 0.0001
Prior GI bleeding 61 (7.8) 438 (3.3) <0.0001
Anemia (hemoglobin <13 g/dl in men,
<12 g/dl in women)*
194 (25.1) 1,782 (13.5) <0.0001
Creatinine clearance, ml/min/1.73 m2 63 (49–82) 68 (52–87) <0.0001
Prior ASA use 330 (42.3) 4,864 (36.2) <0.0001
Prior vitamin K antagonist use 519 (66.5) 8,370 (62.2) 0.018
Values are median (25th–75th percentiles) or n (%). *Data not available: left ventricular (LV) dysfunction status: n ¼ 3,557; chronic obstructive
pulmonary disease (COPD): n ¼ 6; alcohol use: n ¼ 1; smoking: n ¼ 3; and anemia: n ¼ 270.
AF ¼ atrial ﬁbrillation; ASA ¼ acetylsalicylic acid; CHADS2 ¼ congestive heart failure, hypertension, age 75 years, diabetes mellitus, prior stroke,
transient ischemic attack (TIA), or noncentral nervous system thromboembolism (doubled); CNS ¼ central nervous system; DBP ¼ diastolic blood
pressure; EF ¼ ejection fraction; GI ¼ gastrointestinal; ROCKET AF ¼ Rivaroxaban Once-daily oral Direct Factor Xa Inhibition Compared with Vitamin K
Antagonism for Prevention of Stroke and Embolism Trial in Atrial Fibrillation; SBP ¼ systolic blood pressure; TIA ¼ transient ischemic attack.
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897large amounts of tissue factor in the cerebral vascular beds
could modulate vascular hemostatic activity within brain
vessels whereby warfarin decreases factor VII activity, but the
newer agents do not affect the tissue factor-factor VIIa
complex (17). It has been postulated that higher rates of GI
bleeding with rivaroxaban (and dabigatran) relative to
warfarin could be due to exacerbation of surface bleeding by
the presence of active anticoagulant in the gut. Whereas
warfarin has over 99% bioavailability and unabsorbed
warfarin is inactive, all of the new oral anticoagulants are
partially excreted in the feces as active drug (19).Application of established bleeding risk scores in
ROCKET AF. Although the performance of the ATRIA
and HAS-BLED predictive bleeding risk scores in the
ROCKET AF population was limited, a number of quali-
ﬁcations must be taken into account. For example, the
ROCKET AF trial did not record and/or measure in a
different manner some of the variables (e.g., hypertension).
In addition, the ROCKET AF trial speciﬁcally excluded
some patients with hemorrhagic risk-related criteria and/
or concomitant conditions. Furthermore, although HAS-
BLED requires determination of “labile INR” status (on the
Table 4 HAS-BLED Score in ROCKET AF Trial and Original HAS-BLED Cohort
Score
ROCKET-AF HAS-BLED Cohort
Major Bleedings Patient-Yrs of Follow-Up Bleeds/100 Patient-Yrs Major Bleedings Bleeds/100 Patient-Yrs
0 1 255.2 0.71 9 1.13
1 45 2,686.3 2.81 13 1.02
2 201 9,323.0 2.95 14 1.88
3 330 7,643.7 3.63 7 3.74
4 170 2,087.0 4.37 4 8.70
5 31 139.8 5.51 1 12.50
6 2 2.0 7.07 0 0.00
Any score 780 22,137.0 3.52 48 1.56
c-index 0.546 0.72
HAS-BLED ¼ Hypertension, Abnormal renal/liver function, Stroke, Bleeding history, Labile International Normalized Ratio, Elderly, Drugs/alcohol; ROCKET AF ¼ Rivaroxaban Once-daily oral Direct Factor
Xa Inhibition Compared with Vitamin K Antagonism for Prevention of Stroke and Embolism Trial in Atrial Fibrillation.
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898basis of TTR <60%) (7) while on a regimen of vitamin K
antagonist therapy, the ROCKET AF study design (re-
quirement for discontinuation of warfarin and an INR <3.0)
precluded accurate INR assessment pre-randomization.
Therefore, although this cohort described 781 major
bleeding events over a median 19-month time period, the
low predictive value of the HAS-BLED and ATRIA risk
scores in the ROCKET AF population might be more a
reﬂection of incomplete variable information than a lack
of validity of these schemas. Furthermore, the discriminatory
capacity of bleeding risk scores seems relatively limited (e.g.,
c-indexes in the 0.70 range) in both original model develop-
ment and subsequent validation cohorts (20). Finally, no trials
have shown the value of withholding stroke prevention
therapy in patients with a high bleeding risk score, and it
remains unclear as to what bleeding risk threshold would lead
to an alternative (or no) antithrombotic strategy employment.
Factors associated with major bleeding in ROCKET AF.
We identiﬁed increasing age, prior (GI) bleeding, anemia at
baseline, and (pre-randomization) ASA use as independent
predictors of major bleeding, consistent with ﬁndings fromTable 5 ATRIA Score in ROCKET AF Trial and Original ATRIA Cohort
Score
ROCKET-AF
Major Bleedings Patient-Yrs of Follow-Up Blee
0 30 1,264.4
1 234 9,905.8
2 38 760.9
3 259 6,849.5
4 81 1,443.4
5 19 166.3
6 96 1,262.3
7 15 89.6
8 d d
9 0 9.9
10 0 1.2
Any score 772 21,753.5
c-index 0.605
ATRIA ¼ AnTicoagulation and Risk factors In Atrial ﬁbrillation; ROCKET AF ¼ Rivaroxaban Once-daily o
Embolism Trial in Atrial Fibrillation.several studies examining risk factors for anticoagulation-
related bleeding in patients with AF (2–4,6,7,21). Many
studies have also identiﬁed hypertension, including SBP
elevation, as a predictor of major bleeding; in the ROCKET
AF trial we observed a dichotomous relationship between
the risk of bleeding and DBP such that a baseline DBP
90 mm Hg was an independent predictor of increased
risk, whereas a baseline DBP <90 mm Hg was associated
with a signiﬁcantly lower risk. Female sex has also been
noted in some studies to be associated with an increased risk
of bleeding with warfarin in patients with either AF (2,22)
or acute venous thromboembolism (5); in contrast, in the
ROCKET AF trial women were at signiﬁcantly lower risk
for major bleeding. Finally, we identiﬁed that a history of
COPD, presumably a marker for important comorbidity
(23), was associated with an increased risk for major
bleeding.
Some differences in major bleeding rates were noted ac-
cording to race and region with associated signiﬁcant
interaction p values (Fig. 2). However, race was not a sig-
niﬁcant predictor of major bleeding in univariate analysis,ATRIA Cohort
ds/100 Patient-Yrs Major Bleedings Bleeds/100 Patient-Yrs
2.37 9 0.48
2.36 14 0.58
4.99 14 0.78
3.78 38 1.27
5.61 18 2.41
11.42 13 4.18
7.61 31 5.11
16.74 5 3.56
d 4 23.11
0.00 6 10.13
0.00 2 16.34
3.55 154 1.40
0.74
ral Direct Factor Xa Inhibition Compared with Vitamin K Antagonism for Prevention of Stroke and
Table 6
Multivariable Model Predicting Major Bleeding
in the ROCKET AF Cohort
Independent Predictor HR 95% CI Chi-Square p Value
Age (per 5-yr increase) 1.17 1.12–1.23 53.0 <0.0001
Sex (female vs. male) 0.82 0.70–0.95 6.7 0.009
DBP <90 mm Hg
(per 5-mm Hg increase)
0.92 0.89–0.96 17.7 <0.0001
DBP 90 mm Hg
(per 5-mm Hg increase)
1.28 1.11–1.47 12.0 0.0005
History of COPD 1.29 1.05–1.58 5.8 0.016
History of GI bleeding 1.88 1.44–2.45 21.9 <0.0001
Prior use of aspirin 1.42 1.23–1.64 22.8 <0.0001
Anemia at baseline 1.88 1.59–2.22 53.8 <0.0001
The c-index for this model was 0.6445; adding the interaction between history of GI bleeding 
prior use of aspirin (p ¼ 0.043) improved the c-index marginally to 0.6453.
Abbreviations as in Tables 1 and 3.
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899and regional differences are confounded by multiple differ-
ences in baseline characteristics. For example, North
American patients were much older and had a higher pro-
portion of comorbidities associated with higher bleedingFigure 3 Blood Pressure at Randomization and Major Bleeding
Univariate relationship between systolic (SBP) and diastolic (DBP) blood pressure
at randomization and major bleeding (at 2 years). Solid lines are predicted
probabilities of major bleeding at 2 years; dashed lines are 95% conﬁdence
intervals. p values for linearity test in both ﬁgures >0.0001. SBP (2 linear
segments, <135, 135): chi-square: 16.53, p ¼ 0.0003, c-index: 0.5326; DBP
(2 linear segments, <90, 90): chi-square: 51.71, p < 0.0001, c-index: 0.5678.rates (e.g., hypertension, anemia). Alternatively, these sub-
group ﬁndings of a single component of the primary safety
endpoint might be simply due to chance; this potential
explanation is supported, because no difference in region was
observed when examining the composite endpoint of major
bleeding and clinically relevant nonmajor bleeding. Thus, we
did not include race or region in our multivariable model but
rather all of the previously established baseline characteristics
associated with bleeding.
Study limitations. We did not identify other predictors
such as renal dysfunction, liver disease, or prior stroke as
independent predictors of major bleeding, in contrast to
some other studies. Although warfarin has no renal
metabolism, rivaroxaban has a dual mode of elimination.
Approximately one-third of rivaroxaban is eliminated un-
changed by the kidneys with the remaining approximately
two-thirds of the drug being metabolized by the liver, after
which one-half of the metabolized fraction is excreted in
urine and the other one-half is excreted in feces (11).
Therefore, patients were excluded from the ROCKET AF
trial if their estimated creatinine clearance was <30 ml/min
at the screening visit, and those included in the trial with
moderate renal dysfunction (creatinine clearance 30 to
49 ml/min; n ¼ 2,950 [20.7%]) received a reduced dose
of rivaroxaban (15 mg instead of 20 mg) on the basis of
extensive pharmacodynamic data and pharmacokinetic
modeling (24). Although ROCKET AF patients with
moderate renal dysfunction had higher rates of stroke and
bleeding than those with normal renal function, there was no
evidence of heterogeneity in treatment effect across dosing
groups, and the ﬁndings with rivaroxaban were consistent
with the overall trial, in comparison with dose-adjusted
warfarin (e.g., fatal bleeding occurred less often with rivar-
oxaban) (24). The ROCKET AF trial is unique among
contemporary studies comparing novel anticoagulants with
warfarin in AF with respect to overall stroke risk on the
basis of the inclusion of 55% of patients with prior stroke,
TIA, or systemic embolism. Therefore, although prior stroke
has been identiﬁed in some studies of AF patients on a
regimen of oral anticoagulation as an independent risk
factor for major bleeding (3,4), more than 1 in 2 patients in
the ROCKET AF trial had a prior event, and this might
have impacted the potential independent predictive value of
previous stroke in our population.
Conclusions
Our analyses of bleeding from the ROCKET AF trial
indicate that rivaroxaban compared with warfarin provides
important safety beneﬁts in patients with AF at moderate-
to-high risk for stroke or systemic embolism. Despite
higher rates of bleeding from GI sites and bleeding that
led to a drop in hemoglobin level or was treated with
transfusion, rivaroxaban compared with warfarin led to a
similar overall risk of major and nonmajor clinically relevant
bleeding and a lower risk of intracranial hemorrhage and
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900fatal bleeding. We identiﬁed, consistent with previous
studies, several baseline factors associated with the risk of
major bleeding, including age, sex, DBP, prior (GI) bleeding
and ASA use, and anemia. Careful assessment of bleeding
risk in patients with AF is required to support clinical de-
cision making for stroke prevention therapy. With the
exception of prior GI bleeding, which was signiﬁcantly
associated with major bleeding in patients randomized to
rivaroxaban but not warfarin, the identiﬁed risk factors for
bleeding had the same association in both oral anti-
coagulation groups. Finally, it is important to recognize that
risk of major bleeding must be placed in the context of
stroke prevention demonstrated with anticoagulation ther-
apy, especially because some factors associated with an
increased risk of bleeding are also associated with the risk
of stroke; indeed, no study has demonstrated improved
outcome on the basis of bleeding risk assessment.
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